CHMP recommends conditional EU approval of Roche ’s Polivy for people with previously treated aggressive lymphoma

Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy ® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news